4-Aminopyridine (4-AP) strongly increases transmitter release from motor nerve terminals (Molgo et al., 1975; Vizi et al., 1977; Lundh, 1978) , probably by affecting a voltage-dependent calcium permeability in the nerve terminal membrane, and thereby enhancing the influx of calcium ions during the nerve terminal action potential (Lundh and Thesleff, 1977) . The drug has recently been shown to restore neuromuscular transmission in the myasthenic syndrome associated with bronchogenic carcinoma (Lundh et al., 1977b) , and in paralysis produced by experimental botulinum toxin poisoning in the rat (Lundh et al., 1977a) . Since 4-AP also enhances transmitter release from normal nerve terminals during repetitive nerve activity (Lundh, 1978) , it might also be of value in the treatment of postsynaptic disorders of neuromuscular transmission such as myasthenia gravis. In this condition muscular weakness is believed to be caused by blockade of acetylcholine receptors by humoral antibodies (Grob, 1976) .
Patients
The effects of 4-AP were tested by intravenous injections of the drug in repeated doses in six patients. All patients had characteristic clinical histories of myasthenia gravis and in all cases muscle power increased after edrophonium or neostigmine injections. At 
Methods
Different batches of 4-aminopyridine (Sigma Co, US) were identified by spectrophotometry and melting point measurements, and the batches were examined for purity by the determination of concentrations of inorganic salts and metals. Batches that passed the purity levels determined by Swedish National Medical Authorities (in Pharmacopea Nordica) were sterilised by millipore filtering, and the sulphate salt (see Lundh et al., 1977b) was prepared for human usage. The solutions used for injection were buffered to pH 7. The injections were made by repeated doses (concentration 5 mg/ ml) in the cubital vein or in a hand vein.
When performing the tests certain precautions for medical emergencies were taken. 4-Aminopyridine has a known analeptic effect (Lemeignan, 1970 (Lemeignan, , 1972 (Lemeignan, , 1973 , and in case 6, who had a history of epileptic fits, the electroencephalogram was recorded continuously during the test. Recording of electrocardiogram, blood pressure, pulse rate, and respiratory rate were made repeatedly.
Ethical considerations were also taken into account. The project was accepted by an independent Ethics Committee of the hospital as well as by Swedish Government Medical Authorities. The patients participating in the tests gave their consent after objective information.
Conventional electrophysiological techniques were used to record the compound muscle action potential (CMAP) by surface electrodes on the thenar, hypothenar, deltoid, and infraorbital muscles during single and repetitive stimulation of the corresponding motor nerve at frequencies from 1 to 20 per second. Figure. This patient (case 2), as well as cases 1 and 3, showed a marked decrement of CMAP at low and moderately high stimulus frequencies, and little frequency potentiation after high frequency stimulation. Injection of 4-AP caused almost a normalisation of the decrement at 2 stimuli/second in case 2. (Figure, B as compared with G), and a considerable improvement at the other frequencies tested. For case 3 the decremental response in the infraorbital muscle was normalised, and in case 1 the decrements were reduced in infraorbital as well as the thenar muscles. Case 4 exhibited somewhat atypical electrophysiological results with a significant decrement only at relatively high stimulus frequencies (10-20 per second). A short lasting normalisation was observed after 4-AP in this case.
Results

CLINICAL OBSERVATIONS
Two patients (cases 5 and 6) showed a marked frequency potentiation of the CMAP amplitude. In case 5, 4-AP caused an increase of the previously reduced CMAP amplitude, whereas the decremental response was not influenced. In case 6, 4-AP was tested when the patient was still under the influence of neostigmine and caused a further enhancement of the CMAP amplitude as well as a reduction of decrement. Also in case 1, 4-AP produced a further improvement of decrement in the infraorbital muscle in addition to the effect produced by neostigmine.
Discussion
Our results show that 4-AP is able to improve neuromuscular transmission in myasthenia gravis. The drug has a mechanism of action different from anticholinesterases, and it might improve the clinical status and neuromuscular transmission in patients already receiving optimal treatment with conventional drugs. It is possible that in the future 4-AP may be a valuable supplementary drug in the treatment of myasthenia gravis. Previous results in 174 H. Lundh, 0. Nilsson, and 1. Rose'n Table 2 Electrophysiological test parameters in the patients tested with 4-AP (10-20 mg intravenously). In GR (case 1) test 2, and BJ (case 6) the effects of the addition of 4-AP after 0.5 mg neostigmine are described. CMAP=compound muscle action potential. the Eaton-Lambert syndrome (Lundh et al., 1977b) have demonstrated that the drug is active when given continuously orally. The adverse side effects observed after injection of 4-AP included subjective instability on walking, anxiety, and perioral paraesthesia. 4-AP has previously been reported to cause photophobia (Lundh et al., 1977b) , and produces ataxia in patients with senile dementia (unpublished) . The side effects may be caused by actions on the central nervous system, since 4-AP is known to stimulate powerfully reflex activity and synaptic transmission in the brain and spinal cord (Lemeignan, 1970 (Lemeignan, , 1972 (Lemeignan, , 1973 Jankowska et al., 1977 Efiects of 4-aminopyridine in myasthenia gravis be possible to combine 4-AP in a dose not producing side effects with anticholinesterase medication. Sensitivity to side effects also seems to differ between individuals.
In myasthenia gravis the neuromuscular block is assumed to be postsynaptic and caused by decreased acetylcholine sensitivity of the muscle membrane (Grob, 1976) . It is not known if transmitter release in myasthenia gravis is normal, but studies on the release process in this disease have demonstrated normal or increased quantum content of endplate potentials (Elmqvist et al., 1964; Cull-Candy et al., 1978) . If the reduction of miniature endplate potential amplitude observed in this disease (Elmqvist et al., 1964 ) is caused by postsynaptic blockade of the acetylcholine receptors, it is, therefore, reasonable to assume that, in general, transmitter release in myasthenia gravis is not reduced. A-AP acts by increasing transmitter release from nerve terminals, and in paralysis caused by reduced transmitter release like botulinum toxin poisoning (Lundh et al., 1977a) and the Eaton-Lambert syndrome (Lundh et al., 1977b ) the drug powerfully increases the amount of transmitter released by each nerve impulse during tetanic nerve activity and restores neuromuscular transmission. In conditions in which transmitter release is normal, A-AP is less potent but still markedly enhances transmitter release during repetitive nerve activity at frequencies below 50 per second (Lundh, 1978) . This may explain the improvement of neuromuscular transmission produced by 4-AP in myasthenia gravis.
The observation of a marked enhancement of the CMAP by 4-AP in some patients with clinical myasthenia gravis is compatible with a postsynaptic blockade of neuromuscular transmission. However, its combination with a marked frequency potentiation after maximal voluntary contraction implies that these patients may have a presynaptic neuromuscular block in addition to the postsynaptic defect.
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